| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639310 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US9974790 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
|
US10639310 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US9974790 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
| US10610530 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(4 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(4 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US10610530 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
| US10758543 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US10869870 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US11590136 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
| US11571425 | INCYTE CORP | NA |
May, 2031
(7 years from now) | |
| US11219624 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(7 years from now) | |
|
US10869870 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
|
US11219624 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
|
US10758543 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(8 years from now) | |
| US11590138 | INCYTE CORP | Topical treatment of vitiligo by a jak inhibitor |
Jun, 2040
(16 years from now) | |
| US11510923 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(16 years from now) | |
| US11590137 | INCYTE CORP | Ruxolitinib formulation for reduction of itch in atopic dermatitis |
Sep, 2040
(16 years from now) | |
| US11602536 | INCYTE CORP | Topical treatment of vitiligo by a JAK inhibitor |
May, 2041
(17 years from now) | |
Opzelura is owned by Incyte Corp.
Opzelura contains Ruxolitinib Phosphate.
Opzelura has a total of 28 drug patents out of which 0 drug patents have expired.
Opzelura was authorised for market use on 21 September, 2021.
Opzelura is available in cream;topical dosage forms.
Opzelura can be used as for topical treatment of moderate ad in non-immunocompromised patients, with baseline bsa of 3-20% and itch nrs score of =4, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of phototherapy, wherein the vitiligo affects at least one of the lower extremities, trunk, and feet of the patient, for topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older; for topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of laser or phototherapy, wherein the vitiligo affects at least one of the lower extremities, trunk, and feet of the patient.
The generics of Opzelura are possible to be released after 05 May, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 21, 2024 |
| New Indication (I) | Jul 18, 2025 |
| Pediatric Exclusivity (PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...
Dosage: CREAM;TOPICAL
OPZELURA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic